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Background. The role of genetic factors in the predisposition to develop ischemic stroke has been assessedby previous studies. The
main goal of the current study was to determine any possible role of TNF-857C>T, TNFRSF1A36A>G, and TNFRSF1B676T>G
polymorphisms in risk for stroke. Materials and Methods. One hundred seventy-three patients with ﬁrst ever ischemic stroke of
solely atherosclerotic etiology in Northwest Greece and a control group of 179 healthy unrelated subjects were evaluated. Results.
TNFα-857TT, TNFR136AA,a n dTNFR2676TT genotypes were signiﬁcantly increased in the patient group compared to controls
(P = .008, OR = 2.47 (1.26–4.84), P = .005, OR = 1.97 (1.22–3.17), and P = .003, OR = 2.2 (1.43–3.37), resp.). In addition,
the TNFR136A and the TNFR2676T alleles were found signiﬁcantly increased in patients compared to controls (P = .009, OR =
1.48 (1.1–2) and P = .001, OR = 1.75 (1.25–2.46), resp.). Conclusion. The high incidence of these genotypes and alleles in patient
group suggests that they are potentially predisposing factors for stroke in the Greek population studied. Large-scale multicenter
controlled studies are needed to verify these polymorphisms eﬀects on stroke susceptibility.
1.Introduction
Ischemic stroke is a multifactorial disease, caused by the in-
teractions of genetic and environmental factors, based on
atherosclerosis and arterial thrombogenesis [1]. Central ner-
vous system (CNS) can mount a well-deﬁned inﬂammatory
response to a variety of insults including ischemia and
atherosclerosis [2]. Atherosclerosis has many inﬂammatory
mediators contributing to atheroma formation, atheroma-
tous injury, rupture of the plaque, and hence to intraluminal
thrombosis [2, 3]. Tumor necrosis factor-(TNF-) alpha is
involved in every step of inﬂammation, from initiation
to downregulation, and elevated levels of TNF and other
cytokines have been demonstrated in the cerebrospinal ﬂuid
(CSF) and the plasma of acute stroke and subarachnoid
hemorrhage patients [4–6]. TNF exerts its biological eﬀects
via the two cell surface receptors that act as physiological
attenuators, TNFRSF1A and TNFRSF1B.
Functional polymorphisms inside the TNF gene pro-
moter and polymorphisms that could inﬂuence the function
or the expression of TNFRSF1 and TNFRSF1B have been
investigatedinvariousimmune,inﬂammatory, andneurode-
generative conditions [7–14] but only few genetic studies
havefocusedontheassociation ofthesepolymorphisms with
stroke [15, 16].
Underthe rationale thatindividualswith geneticvariants
might possibly be at greater risk for ischemic stroke, we ana-
lyzed the role of the TNF-857C>T, TNFRSF1A36A>G,a n d
TNFRSF1B676T>G polymorphisms in ischemic stroke pa-
tients in Northwestern Greece, a rather restricted area with
limited recent immigration.2 Stroke Research and Treatment
2.Materialsand Methods
2.1. Study Population. Cases eligible for recruitment were
173patientshospitalizedwithﬁrsteverischemicstrokeinthe
Stroke Reference Center of Northwestern Greece in a period
of 18 months, from May 2008 to November 2009, deﬁned
according to the WHO deﬁnition, and conﬁrmed by brain
imaging showing a recent brain infarct corresponding to the
clinical presentation. As a control group, 179 age-matched
unrelated subjects were recruited from the same medical
center, among nonfamily visitors. Controls had no history of
previous ischemic cerebrovascular event, established by the
Questionnaire for Verifying Stroke-Free Status(QVSFS)[17]
and normal neurological examination. The study protocol
was in compliance with the Helsinki Declaration, approved
by the Institutional Ethics Committee. An informed consent
was signed by all eligible patients and controls.
In all subjects a detailed medical history was obtained
andathoroughphysicalexamination was performed. Demo-
graphicdata,biochemicalproﬁle,and establishedrisk factors
for stroke were recorded. Arterial hypertension was docu-
mented when systolic blood pressure (BP) was ≥140mmHg
or diastolic BP ≥ 90mmHg or when individuals were receiv-
ing antihypertensive drugs for previously established hyper-
tension. Smoking, active or ceased within the last 3 months,
w a sc o n s i d e r e da sc u r r e n t .D i a b e t e sm e l l i t u sw a sc o n s i d e r e d
as present if fasting glucose was >126mg/dl or the individual
was treated with antidiabetic medication. Dyslipidemia was
deﬁned as fasting cholesterol >220mg/dl or the individual
was on current treatment with speciﬁc antilipidemic agents.
Further evaluation of the patients included triplex ultra-
sound imaging or CT angiography of extracranial or/and
intracranial arteries, electrocardiogram (ECG),echocardiog-
raphy (transthoracic or transesophageal), and clinical/labo-
ratory assessment to rule out systemic thrombotic and auto-
immune disorders.
Recruitment in the study was performed according to
TOAST deﬁnitions and included patients with lacunars
(small, subcortical, hypodense lesions with a diameter less
than 15mm and corresponding to lesion clinical lacunar
syndrome) and patients with large artery atherosclerosis
(hypodense lesions with a diameter >15mm and >50%
stenosis in the appropriate intracranial artery) [18].
Cardioembolic strokes were excluded since they could
resultfrom diﬀerentetiology(e.g.,atrial ﬁbrillation). Strokes
occurred in the course of systemic conditions such as coag-
ulopathies or immunological disorders or of undetermined
etiology were also excluded in order to assure the solely ath-
erosclerotic etiology of the stroke.
2.2. Genetic Analysis. Genomic DNA was extracted from
peripheral blood lymphocytes according to the standard
salt extraction procedure. Polymorphisms TNF-857C>T
(rs1799724), TNFRSF1A36A>G (rs767455), and TNFRSF1B-
676T>G (rs1061622) were ampliﬁed using the following
primer pairs: 36F: 5 -GAG CCC AAA TGG GGG AGT -
GAG AGG-3  36R: 5 -ACC AGG CCC GGG CAG GA-
GA G - 3  , 676F: 5 -ACT CTC CTA TCC TGC CTG CT-
3  676R: 5 -TTC TGG AGT TGG CTG CGT GT-3 ,a n d
857F: 5 -AAG TCG AGT ATG GGG ACC CCC CGT TA-
A-3  857R: 5 -CCC CAG TGT GTG GCC ATA TCT TCT-
T-3 . Subsequently, restriction assays were employed using
the restriction endonucleases MspA1 I, Nla III, and Hinc II,
respectively. All samples were run in duplicates with positive
and negative for each genotype samples as controls and
blanks.
2.3. Statistical Analysis. The Chi-square test was used to test
theagreementofgenotypefrequencieswithHardy-Weinberg
equilibrium expectations. Binary data were described as
percentages, while continuous data were expressed as the
mean ± standard deviation (SD). We calculated odds ratios
and 95% conﬁdence intervals (CIs) to compare allele and
genotype distributions. All tests were two-sided with 95%
signiﬁcance level (P<. 05). The statistical analysis was
performed with the statistical package StatXact 3.0 (Cytel
Inc., Cambridge, Mass, USA).Furthermore, a power analysis
showed that at least 302 subjects should be recruited in
each group (cases and controls) for TNF-857C>T, 272
subjectsforTNFRSF1A36A>G,and85subjectsineachgroup
for TNFRSF1B676T>G polymorphism, if the study power
required was 80 per cent with a signiﬁcance level of 0.05.
3.Results
Of 173 patients, 113 (65%) were men and 60 (35%) were
women with a mean age of 58.6 (SD ± 7.2 years). Of 179
controls, 123 (69%) were men and 56 (31%) were women
and mean age was 57.1 (SD ± 5.9 years). Patients and
controls demographics are shown in Table 1.I nt e r m so f
stroke subtype, 84 patients had lacunar strokes, whereas 89
patients had large artery strokes.
The genotype frequencies for all three polymorphisms
were in Hardy-Weinberg equilibrium in healthy controls.
The genotype frequencies for TNFRSF1A and TNFRSF1B
polymorphisms were in Hardy-Weinberg equilibrium in
patients. Regarding the TNF-857C>T polymorphism dis-
tribution, a high prevalence of TT genotype in patients
(P = .008, OR = 2.47 (1.26–4.84)) was revealed, implying
a TT s e l e c t i o ni np a t i e n t sc a u s i ng Hardy-Weinberg disequi-
librium, despite equilibrium in the controls. No statistically
signiﬁcant diﬀerence was observed in the allele frequencies,
to further establish the hypothesis of the TT selection in
patients.
The distributionand frequenciesofgenotypesand alleles
for TNF, TNFRSF1A, and TNFRSF1B are summarized in
Table 2.R e g a r d i n gTNFRSF1A36A>G, a statistically signiﬁ-
cant diﬀerence was observed between patients carrying the
AA genotype and controls (P = .005, OR = 1.97 (1.22–
3.17)). Signiﬁcant diﬀerences were also noted in the allele
frequencies, namely, A and G with 58.1% in patients versus
48.3% in controls for A allele and 41.9% in patients versus
51.7% in controls for G allele (P = .009, OR = 1.48 (1.1–
2)). For the TNFRSF1B676T>G,t h eTT genotype was more
frequent in the stroke group than in controls, with 61.9%
versus 42.5%, respectively (P = .003, OR = 2.2 (1.43–
3.37)). Similarly, statistically signiﬁcant diﬀerences betweenStroke Research and Treatment 3
Table 1: Clinical characteristics of patients and controls.
Data Cases N = 173 Controls N = 179 P values
Male 113 (65) 123 (69) .498
Female 60 (35) 56 (31) .498
Age, mean 58.6 (7.2) 57.1 (5.9) .167
Hypertension 137 (79.1) 129 (72.0) .121
Smoking 74 (42.8) 70 (39.1) .484
Diabetes mellitus 40 (23.1) 31 (17.3) .176
Dyslipidemia 109 (63.0) 99 (55.3) .142
Numbers in parentheses for nominal data indicate percentages and for continuous data SD.
Table 2: Genotypes and alleles in patients and control.
Polymorphisms TNF-857C>T TNFRSF1A36A>G TNFRSF1B676T>G
Genotypes TT CT + CC AA AG + GG TT TG + GG
Patients, n (%) n = 173 30 (17.3) 43 + 100 (24.9 + 57.8) 60 (34.7) 81 + 32(46.8 + 18.5) 107 (61.9) 57 + 9 (32.9 + 5.2)
Controls, n (%) n = 179 14 (7.8) 63 + 102 (35.2 + 57.0) 38 (21.2) 97 + 44 (54.2 + 24.6) 76 (42.5) 89 + 14(49.7 + 78)
P values, OR (95% CI) P = .008, 2.47 (1.26–4.84) P = .005, 1.97 (1.22–3.17) P = .003, 2.2 (1.43–3.37)
Alleles CTA G T G
Patients, n (%) n = 173 243 (70.2) 103 (29.8) 201 (58.1) 145 (41.9) 271 (78.3) 75 (21.7)
Controls, n (%) n = 179 267 (74.6) 91 (25.4) 173 (48.3) 185 (51.7) 241(67.3) 117 (32.7)
P values, OR (95% CI) P = .196, 0.8 (0.57–1.12) P = .009, 1.48 (1.1–2) P = .001, 1.75 (1.25–2.46)
the allele frequencies with 78.3% in patients versus 67.3% in
controls for T allele and conversely 21.7% in patients versus
32.7% in controls for G allele (P = .001, OR = 1.75 (1.25–
2.46)) (Table 2) were revealed.
In terms of stroke subtype, subgroups analysis did not
disclose any statistically signiﬁcant result when genotypes
and alleles distribution in the lacunar stroke group was com-
pared to the large artery atherosclerosis stroke group (data
not shown).
4.Discussion
In the present study, we investigated the association of TNF-
857C>T, TNFRSF1A36A>G, and TNFRSF1B676T>G poly-
morphisms with ischemic stroke, under the rationale that,
as the proinﬂammatory cytokines play an important role
in cerebral ischemia [4, 5, 19, 20], certain TNF and TNF
receptorspolymorphisms may be implicated in strokeoccur-
rence.
A gene located on chromosome 6p21 encodes TNF-α.
The TNF-857C>T polymorphism is a functional polymor-
phism through binding to the transcription factor octamer
transcription factor-1 (OCT-1) [7]. No research group,
working on stroke, has focused on this polymorphism. Most
groups have worked on the TNF-308G>A polymorphism
withPereiraet al.suggestingthat theTNF-308G>Apolymor-
phism may play a role in ischemic stroke [21]s h o w i n gt h a t
young subjects of European ancestry carrying the A allele
(AA + GA versus GG) were associated with a statistically
signiﬁcant increase in the risk of stroke compared with
individuals homozygous for the G allele (OR 2.04, P =
.004). In a cohort of young Italian stroke patients, the A
allele of −308G>A polymorphism exerted an independent
eﬀect on predisposition to ischemic stroke in young stroke
patients with AA + GA genotypes frequency being 25.2%
+ 1.7%, respectively, in the stroke group versus 15% + 0.6
5% in the control group [15]. Dissimilar ﬁndings suggest
that this polymorphism is clinically important in stroke in
sicklecellanemiachildren[22]butshowsprotectiveeﬀectsof
TNF(-308)A allele (OR = 0.39, P = .006) with 18% carriers
of the A allele in stroke group versus 38% in the control
group.
In our healthy population in Northwest Greece, as re-
corded in a recent study conducted by our group [10], the
TNF-308G>A polymorphism is not in Hardy-Weinberg
equilibrium,andourstudywasdesignedonthespeciﬁcchar-
acteristics of our population to exclude this polymorphism
and focus on the TNF-857C>T polymorphism. Our study
exerted that this other functional polymorphism plays a role
in stroke development with the recessive genotype being
more frequent in ischemic stroke patients.
TNFRSF1Aisencodedby a genelocatedon chromosome
12p13.2.T h eTNFRSF1A36A>G polymorphism is a silent
mutation in codon 12, and it although has no obvious func-
tionalinﬂuenceonproteinstructure,many studieshavetried
to ﬁnd any association of this polymorphism with speciﬁc
inﬂammatory disease manifestations and response to treat-
ment, such as Multiple Sclerosis (MS), Crohn’s disease, and
Rheumatoid Arthritis (RA) [10, 11, 14].
TNFRSF1Bis encodedby a gene located on chromosome
1 p36.3 with a higher aﬃnity for TNF than TNFRSF1, and
polymorphisms in this receptor aﬀect the binding of TNF
and the pathway involved in inﬂammation; associations of
TNFRSF1B polymorphisms with chronic inﬂammatory dis-
eases such as RA and systemic lupus erythematosus have
been reported [10, 12].4 Stroke Research and Treatment
Our results indicate that the most studied, for many in-
ﬂammatory diseases, polymorphisms of TNFRSF1A and
TNFRSF1B are also associated with stroke, with the AA
genotype of TNFRSF1A and the TT of TNFRSF1B being
more frequent in stroke patients. The same applies for the
A allele of TNFSF1A and the T allele of TNFSF1B.
Limitations of our study include the relatively small
number of patients and the TNF-857TT Hardy-Weinberg
disequilibrium in our cases. As a consequence of the small
number of the cases the power ofour study is limited regard-
ing the TNF-857C>T and the TNFRSF1A36A>G polymor-
phism. Regarding the TNFRSF1B676T>G polymorphism,
power analysis conﬁrmed a sound power of this result. The
strengths of the study were the solely atherosclerotic etiology
of subjects and the prospective design with all ischemic
stroke patients under certain inclusion criteria and the
signiﬁcant result for TNFRSF1B676T>G polymorphism.
5.Conclusions
Conclusively, our results indicate a possible association of
−857C>T polymorphism of TNF with stroke and are in
favorofadirect,contributoryeﬀectofthemost studiedpoly-
morphisms of TNFRSF1A and TNFRSF1B on ischemic
stroke predisposition, with TNFRSF1B676T>G polymor-
phism showing the closest association. Our assumption is
that speciﬁc polymorphisms are involved in the process of
inﬂammation, and thustheypromoteextra- and intracranial
atherosclerosis and subsequently strokes. The genetically
homogenous population allows the extractions of assump-
tions concerning our population, but no further conclusions
should be reached without large-scale multicenter studies
and a wider range of results. Any role for TNF and TNF
receptor genes on stroke is far from being established with
these genesbeing excellent candidatesforfurther research on
the genetics of stroke.
Funding
This paperispart ofthe03EDresearch project,implemented
within the framework of the Reinforcement Programme of
Human Research Manpower and coﬁnanced by National
and Community Funds (25% from the Greek Ministry of
Development-General Secretariat of Research and Technol-
ogy and 75% from European Union Social Fund).
References
[ 1 ]J .Y .U m ,N .H .A n ,a n dH .M .K i m ,“ T N F - α and TNF-β gene
polymorphisms in cerebral infarction,” Journal of Molecular
Neuroscience, vol. 21, no. 2, pp. 167–171, 2003.
[ 2 ]B .A r v i n ,L .F .N e v i l l e ,F .C .B a r o n e ,a n dG .Z .F e u e r s t e i n ,
“The role of inﬂammation and cytokines in brain injury,”
Neuroscience and Biobehavioral Reviews,v o l .2 0 ,n o .3 ,p p .
445–452, 1996.
[3] R. Ross,“Atherosclerosis—aninﬂammatorydisease,” The New
England Journal of Medicine, vol. 340, pp. 115–126, 1999.
[4] A. J. Grau, M. Aulmann, C. Lichy et al., “Increased cytokine
release by leucocytes in survivors of stroke at young age,”
European Journal of Clinical Investigation, vol. 31, no. 11, pp.
999–1006, 2001.
[5] N. Vila, J. Castillo, A. Davalos, and A. Chamorro, “Proin-
ﬂammatory cytokines and early neurological worsening in
ischemic stroke,” Stroke, vol. 31, no. 10, pp. 2325–2329, 2000.
[6] K. A. Hanafy, B. Grobelny, L. Fernandez et al., “Brain inter-
stitial ﬂuid TNF-α after subarachnoid hemorrhage,” Journal of
the Neurological Sciences, vol. 291, no. 1-2, pp. 69–73, 2010.
[ 7 ]D .A .V a nH e e l ,I .A .U d a l o v a ,A .P .D eS i l v ae ta l . ,“ I n ﬂ a m -
matory bowel disease is associated with a TNF polymorphism
that aﬀects an interaction between the OCT1 and NF(-
kappa)B transcription factors,” Human Molecular Genetics,
vol. 11, no. 11, pp. 1281–1289, 2002.
[8] C. Cipriano, C. Caruso, D. Lio et al., “The -308G/A polymor-
phism of TNF-α inﬂuences immunological parameters in old
subjects aﬀected by infectious diseases,” International Journal
of Immunogenetics,vol. 32, no. 1, pp. 13–18, 2005.
[ 9 ]D .L i o ,G .C a n d o r e ,A .C o l o m b oe ta l . ,“ Ag e n e t i c a l l yd e t e r -
mined high setting of TNF-α inﬂuences immunologicparam-
eters of HLA-B8,DR3 positive subjects: implications for
autoimmunity,” Human Immunology, vol. 62, no. 7, pp. 705–
713, 2001.
[ 1 0 ]A .C h a t z i k y r i a k i d o u ,I .G e o r g i o u ,P .V .V o u l g a r i ,A .I .V e n e t -
sanopoulou, and A. A. Drosos, “Combined tumour necrosis
factor-α and tumour necrosis factor receptor genotypes could
predict rheumatoid arthritis patients’ response to anti-TNF-α
therapy and explain controversies of studies based on a single
polymorphism,” Rheumatology, vol. 46, no. 6, pp. 1034–1035,
2007.
[11] P. L. De Jager, X. Jia, J. Wang et al., “Meta-analysis of genome
scans and replication identify CD6, IRF8 and TNFRSF1A as
new multiplesclerosissusceptibility loci,”Nature Genetics,vol.
41, no. 7, pp. 776–782, 2009.
[12] C. Morita, T. Horiuchi, H. Tsukamoto et al., “Association of
tumor necrosis factor receptor type II polymorphism 196R
with systemic lupus erythematosus in the Japanese molecular
andfunctionalanalysis,”Arthritis andRheumatism,vol.44,no.
12, pp. 2819–2827, 2001.
[13] B. Wang, S. Zhou, ZE. Yang et al., “Genetic analysis of
tumor necrosis factor-α (TNF-α) G-308A and Saitohin Q7R
polymorphisms with Alzheimer’s disease,” Journal of the
Neurological Sciences, vol. 270, no. 1-2, pp. 148–151, 2008.
[ 1 4 ]M .F a b r i s ,B .T o l u s s o ,E .D iP o i ,R .A s s a l o n i ,L .S i n i g a g l i a ,a n d
G. Ferraccioli, “Tumor necrosis factor-α receptor II polymor-
phism in patients from Southern Europe with mild-moderate
andsevererheumatoidarthritis,”Journal ofRheumatology,v ol.
29, no. 9, pp. 1847–1850, 2002.
[15] S. Rubattu, R. Speranza, M. Ferrari et al., “A role of TNF-α
gene variant onjuvenile ischemicstroke: a case-control study,”
European Journal of Neurology, vol. 12, no. 12, pp. 989–993,
2005.
[16] W. Lalouschek, M. Schillinger, K. Hsieh et al., “Polymor-
phisms of the inﬂammatory system and risk of ischemic
cerebrovascular events,” Clinical Chemistry and Laboratory
Medicine, vol. 44, no. 8, pp. 918–923, 2006.
[17] W. J. Jones, L. S. Williams, and J. F. Meschia, “Validating the
questionnaire for Verifying Stroke-Free Status (QVSFS) by
neurological history and examination,” Stroke, vol. 32, no. 10,
pp. 2232–2236, 2001.
[18] L. B. Goldstein, M. R. Jones, D. B. Matchar et al., “Improving
the reliability of stroke subgroup classiﬁcation using the Trial
of ORG 10172 in Acute Stroke Treatment (TOAST) criteria,”
Stroke, vol. 32, no. 5, pp. 1091–1096, 2001.Stroke Research and Treatment 5
[19] L. S. Rallidis, M. Vikelis, D. B. Panagiotakos, G. K. Liakos, E.
Krania, and D. T. Kremastinos, “Usefulness of inﬂammatory
and haemostatic markers to predict short-term risk for death
in middle-aged ischaemic stroke patients,” Acta Neurologica
Scandinavica, vol. 117, no. 6, pp. 415–420, 2008.
[20] J. Zaremba and J. Losy, “Early TNF-α levels correlate with
ischaemic stroke severity,” Acta Neurologica Scandinavica,v o l .
104, no. 5, pp. 288–295, 2001.
[ 2 1 ]T .V .P e r e i r a ,M .R u d n i c k i ,R .F .F r a n c o ,A .C .P e r e i r a ,a n dJ .
E. Krieger, “Eﬀect of the G-308A polymorphism of the tumor
necrosis factorα gene ontherisk ofischemicheart diseaseand
ischemicstroke:a meta-analysis,”American Heart Journal,v o l .
153, no. 5, pp. 821–830, 2007.
[22] C.Hoppe, W.Klitz,K.D’Harlingue et al.,“Conﬁrmationofan
association between the TNF(-308) promoter polymorphism
and stroke risk in children with sicklecell anemia,”Stroke,v o l .
38, no. 8, pp. 2241–2246, 2007.